Michael S. Brown - Mar 29, 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Ownership	Footnotes
transaction	REGN	Common Stock	Options Exercise	$569 K	+1.52 K	+140.67%	$374.12	2.6 K	Mar 29, 2022	Direct	F1
transaction	REGN	Common Stock	Sale	-$1.06 M	-1.52 K	-58.45%	$699.00	1.08 K	Mar 29, 2022	Direct	F1
transaction	REGN	Common Stock	Options Exercise	$153 K	+408	+37.71%	$374.12	1.49 K	Mar 30, 2022	Direct	F1
transaction	REGN	Common Stock	Sale	-$285 K	-408	-27.38%	$699.00	1.08 K	Mar 30, 2022	Direct	F1
holding	REGN	Common Stock						5 K	Mar 29, 2022	by SLAT	F2
holding	REGN	Common Stock						7.16 K	Mar 29, 2022	by Trust

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REGN	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-1.52 K	-34.9%	$0.00	2.84 K	Mar 29, 2022	Common Stock	1.52 K	$374.12	Direct	F1, F3
transaction	REGN	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-408	-14.37%	$0.00	2.43 K	Mar 30, 2022	Common Stock	408	$374.12	Direct	F1, F3

Id	Content
F1	Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2	These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F3	On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.